Imatinib Terminated Phase 3 Trials for Leukemias Treatment

IndicationsStatusPurposePhase
TerminatedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00362466A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy